Theranexus SA logo

ALTHX - Theranexus SA News Story

€3.27 0.0  1.2%

Last Trade - 28/01/22

Sector
Healthcare
Size
Micro Cap
Market Cap £12.3m
Enterprise Value £5.73m
Revenue £n/a
Position in Universe 743rd / 849

BRIEF-Theranexus And BBDF Obtain European Orphan Medicinal Product Designation For BBDF-101 In Batten Disease

Wed 21st October, 2020 5:11pm
Oct 21 (Reuters) - Theranexus SA  ALTHX.PA :
    * ANNOUNCED EUROPEAN COMMISSION'S DECISION TO AWARD "ORPHAN
MEDICINAL PRODUCT" DESIGNATION TO TWO ACTIVE INGREDIENTS,
TREHALOSE AND MIGLUSTAT, USED IN DRUG CANDIDATE BBDF-101 FOR
BATTEN DISEASE
    * UNDER AGREEMENT BETWEEN THERANEXUS AND BBDF, THERANEXUS
HAS
EXCLUSIVE, GLOBAL LICENSE FOR DEVELOPMENT AND COMMERCIAL USE OF
ITS DRUG CANDIDATE BBDF-101 FOR JUVENILE BATTEN DISEASE

Source text for Eikon:  ID:nACT65687 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.